AR035668A1 - Imidazoquinolinas y 6,7,8,9-tetrahidroimidazoquinolinas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos - Google Patents

Imidazoquinolinas y 6,7,8,9-tetrahidroimidazoquinolinas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos

Info

Publication number
AR035668A1
AR035668A1 ARP010105730A ARP010105730A AR035668A1 AR 035668 A1 AR035668 A1 AR 035668A1 AR P010105730 A ARP010105730 A AR P010105730A AR P010105730 A ARP010105730 A AR P010105730A AR 035668 A1 AR035668 A1 AR 035668A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkenyl
compounds
aryl
heteroaryl
Prior art date
Application number
ARP010105730A
Other languages
English (en)
Spanish (es)
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Publication of AR035668A1 publication Critical patent/AR035668A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
ARP010105730A 2000-12-08 2001-12-10 Imidazoquinolinas y 6,7,8,9-tetrahidroimidazoquinolinas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos AR035668A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25421800P 2000-12-08 2000-12-08

Publications (1)

Publication Number Publication Date
AR035668A1 true AR035668A1 (es) 2004-06-23

Family

ID=22963391

Family Applications (6)

Application Number Title Priority Date Filing Date
ARP010105730A AR035668A1 (es) 2000-12-08 2001-12-10 Imidazoquinolinas y 6,7,8,9-tetrahidroimidazoquinolinas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos
ARP010105729A AR035667A1 (es) 2000-12-08 2001-12-10 Imidazo[4,5-c]quinolin-4-aminas y tetrahidroimidazo[4,5-c]quinolin-4-aminas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos
ARP010105728A AR035666A1 (es) 2000-12-08 2001-12-10 Imidazo[4,5-c]quinolin-4-aminas y tetrahidroimidazo[4,5-c]quinolin-4-aminas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos
ARP010105726A AR035664A1 (es) 2000-12-08 2001-12-10 Imidazo[4,5-c]quinolin-4-aminas y tetrahidroimidazo[4,5-c]quinolin-4-aminas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos
ARP010105727A AR035665A1 (es) 2000-12-08 2001-12-10 Imidazoquinolinas y 6,7,8,9-tetrahidroimidazoquinolinas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos
ARP010105731A AR035669A1 (es) 2000-12-08 2001-12-10 Imidazoquinolinas y 6,7,8,9-tetrahidroimidazoquinolinas, composiciones que las comprenden, y usos de dichos compuestos en la preparacion de medicamentos

Family Applications After (5)

Application Number Title Priority Date Filing Date
ARP010105729A AR035667A1 (es) 2000-12-08 2001-12-10 Imidazo[4,5-c]quinolin-4-aminas y tetrahidroimidazo[4,5-c]quinolin-4-aminas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos
ARP010105728A AR035666A1 (es) 2000-12-08 2001-12-10 Imidazo[4,5-c]quinolin-4-aminas y tetrahidroimidazo[4,5-c]quinolin-4-aminas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos
ARP010105726A AR035664A1 (es) 2000-12-08 2001-12-10 Imidazo[4,5-c]quinolin-4-aminas y tetrahidroimidazo[4,5-c]quinolin-4-aminas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos
ARP010105727A AR035665A1 (es) 2000-12-08 2001-12-10 Imidazoquinolinas y 6,7,8,9-tetrahidroimidazoquinolinas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos
ARP010105731A AR035669A1 (es) 2000-12-08 2001-12-10 Imidazoquinolinas y 6,7,8,9-tetrahidroimidazoquinolinas, composiciones que las comprenden, y usos de dichos compuestos en la preparacion de medicamentos

Country Status (31)

Country Link
US (8) US6683088B2 (enExample)
EP (6) EP1339715A2 (enExample)
JP (7) JP2004515501A (enExample)
KR (6) KR20040028691A (enExample)
CN (6) CN1297554C (enExample)
AR (6) AR035668A1 (enExample)
AT (3) ATE319711T1 (enExample)
AU (12) AU2002239517B2 (enExample)
BR (6) BR0116032A (enExample)
CA (6) CA2431151A1 (enExample)
CY (2) CY1105586T1 (enExample)
CZ (6) CZ20031562A3 (enExample)
DE (3) DE60111076T2 (enExample)
DK (3) DK1341791T3 (enExample)
EE (6) EE200300272A (enExample)
ES (3) ES2242782T3 (enExample)
HR (6) HRP20030467B1 (enExample)
HU (6) HUP0400704A2 (enExample)
IL (6) IL155884A0 (enExample)
MX (6) MXPA03004975A (enExample)
NO (6) NO20032452L (enExample)
NZ (6) NZ526087A (enExample)
PL (7) PL365907A1 (enExample)
PT (2) PT1341790E (enExample)
RU (6) RU2302418C2 (enExample)
SI (1) SI1341790T1 (enExample)
SK (6) SK287732B6 (enExample)
TW (3) TW584633B (enExample)
UA (2) UA74852C2 (enExample)
WO (6) WO2002046193A2 (enExample)
ZA (6) ZA200305272B (enExample)

Families Citing this family (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
JP3436512B2 (ja) * 1999-12-28 2003-08-11 株式会社デンソー アクセル装置
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
UA74852C2 (en) * 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6664265B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6660747B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
WO2003045391A1 (en) 2001-11-29 2003-06-05 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
AU2004220469B2 (en) 2001-11-29 2010-07-29 3M Innovative Properties Company Methods of improving skin quality
CA2365732A1 (en) 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
IL147953A (en) 2002-02-01 2008-04-13 Meir Bialer Derivatives and pharmaceutical compositions of n-hydroxymethyl tetramethylcyclopropyl-
WO2003072026A2 (en) * 2002-02-22 2003-09-04 3M Innovative Properties Company Method of reducing and treating uvb-induced immunosuppression
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
US6797718B2 (en) * 2002-06-07 2004-09-28 3M Innovative Properties Company Ether substituted imidazopyridines
JP4903997B2 (ja) * 2002-07-02 2012-03-28 サザン リサーチ インスティチュート FtsZの阻害剤およびそれらの用途
AU2003299863B2 (en) * 2002-08-15 2009-09-24 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
JP2006503068A (ja) 2002-09-26 2006-01-26 スリーエム イノベイティブ プロパティズ カンパニー 1h−イミダゾダイマー
NZ540826A (en) 2002-12-20 2008-07-31 3M Innovative Properties Co Aryl / hetaryl substituted imidazoquinolines
WO2004060319A2 (en) 2002-12-30 2004-07-22 3M Innovative Properties Company Immunostimulatory combinations
WO2004071459A2 (en) * 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
US7485432B2 (en) * 2003-02-27 2009-02-03 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
EP1601365A4 (en) * 2003-03-04 2009-11-11 3M Innovative Properties Co PROPHYLACTIC TREATMENT OF UV-INDUCED EPIDERMAL NEOPLASIA
KR20050107497A (ko) * 2003-03-07 2005-11-11 쓰리엠 이노베이티브 프로퍼티즈 컴파니 1-아미노 1h-이미다조퀴놀린
US7163947B2 (en) * 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
WO2004080293A2 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Methods for diagnosing skin lesions
AU2004220465A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
US20040192585A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
AU2004229478B2 (en) 2003-04-10 2009-12-24 3M Innovative Properties Company Delivery of immune response modifier compounds
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US20040214851A1 (en) * 2003-04-28 2004-10-28 3M Innovative Properties Company Compositions and methods for induction of opioid receptors
WO2004110991A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
US20050032829A1 (en) * 2003-06-06 2005-02-10 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
AU2004264330A1 (en) * 2003-08-05 2005-02-24 3M Innovative Properties Company Infection prophylaxis using immune response modifier compounds
US8673932B2 (en) 2003-08-12 2014-03-18 3M Innovative Properties Company Oxime substituted imidazo-containing compounds
WO2005018555A2 (en) * 2003-08-14 2005-03-03 3M Innovative Properties Company Lipid-modified immune response modifiers
ES2545826T3 (es) * 2003-08-14 2015-09-16 3M Innovative Properties Company Modificadores de la respuesta inmune modificados con lípidos
US8961477B2 (en) 2003-08-25 2015-02-24 3M Innovative Properties Company Delivery of immune response modifier compounds
US20050048072A1 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
AR045529A1 (es) * 2003-08-27 2005-11-02 3M Innovative Properties Co Imidazoquinolinas sustituidas con grupos ariloxi o arilalquilenoxi
EP1663222A4 (en) * 2003-09-02 2008-05-21 3M Innovative Properties Co METHODS RELATING TO THE TREATMENT OF GIANCES
EP1660026A4 (en) * 2003-09-05 2008-07-16 3M Innovative Properties Co TREATMENT FOR CD5 + B CELL LYMPHOMA
JP2007505629A (ja) * 2003-09-17 2007-03-15 スリーエム イノベイティブ プロパティズ カンパニー Tlr遺伝子発現の選択的調節
MY146124A (en) 2003-10-03 2012-06-29 3M Innovative Properties Co Pyrazolopyridines and analogs thereof
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
AR046046A1 (es) 2003-10-03 2005-11-23 3M Innovative Properties Co Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
AU2004285575A1 (en) * 2003-10-31 2005-05-12 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
CN1906192A (zh) * 2003-11-14 2007-01-31 3M创新有限公司 羟胺取代的咪唑环化合物
WO2005048933A2 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
WO2005054237A1 (en) * 2003-11-21 2005-06-16 Novartis Ag 1h-imidazoquinoline derivatives as protein kinase inhibitors
AR046845A1 (es) * 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
AU2004293078B2 (en) 2003-11-25 2012-01-19 3M Innovative Properties Company Substituted imidazo ring systems and methods
WO2005051324A2 (en) * 2003-11-25 2005-06-09 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2005055932A2 (en) * 2003-12-02 2005-06-23 3M Innovative Properties Company Therapeutic combinations and methods including irm compounds
CA2549216A1 (en) * 2003-12-04 2005-08-25 3M Innovative Properties Company Sulfone substituted imidazo ring ethers
EP1699792A1 (en) * 2003-12-29 2006-09-13 3M Innovative Properties Company Piperazine, 1,4¨diazepane, 1,4¨diazocane, and 1,5¨diazocane fused imidazo ring compounds
US8802853B2 (en) 2003-12-29 2014-08-12 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
AU2004312508A1 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
EP1699398A4 (en) * 2003-12-30 2007-10-17 3M Innovative Properties Co IMPROVING THE IMMUNE RESPONSE
WO2005065678A1 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Immunomodulatory combinations
CA2559607C (en) * 2004-03-15 2013-02-19 3M Innovative Properties Company Immune response modifier formulations and methods
WO2005094531A2 (en) * 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
JP2007532572A (ja) * 2004-04-09 2007-11-15 スリーエム イノベイティブ プロパティズ カンパニー 免疫反応調整剤を送達させるための方法、組成物および調製物
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
WO2005123079A2 (en) * 2004-06-14 2005-12-29 3M Innovative Properties Company Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) * 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
JP5128940B2 (ja) * 2004-06-18 2013-01-23 スリーエム イノベイティブ プロパティズ カンパニー 置換イミダゾキノリン、イミダゾピリジン、およびイミダゾナフチリジン
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006009832A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
WO2006029115A2 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1h imidazo ring systems and methods
AU2005282726B2 (en) * 2004-09-02 2011-06-02 3M Innovative Properties Company 1-alkoxy 1H-imidazo ring systems and methods
WO2006026760A2 (en) * 2004-09-02 2006-03-09 3M Innovative Properties Company 1-amino imidazo-containing compounds and methods
WO2006029223A2 (en) * 2004-09-08 2006-03-16 Children's Medical Center Corporation Method for stimulating the immune response of newborns
JP4769810B2 (ja) * 2004-09-14 2011-09-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド イミダゾキノリン化合物
EP1804583A4 (en) * 2004-10-08 2009-05-20 3M Innovative Properties Co ADJUVANT FOR DNA VACCINE
WO2006063072A2 (en) * 2004-12-08 2006-06-15 3M Innovative Properties Company Immunomodulatory compositions, combinations and methods
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
US7943609B2 (en) 2004-12-30 2011-05-17 3M Innovative Proprerties Company Chiral fused [1,2]imidazo[4,5-C] ring compounds
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
EP1833479A2 (en) * 2004-12-30 2007-09-19 Takeda Pharmaceutical Company Limited 1-(2-methylpropyl)-1h-imidazo 4,5-c(1,5 )naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazoý4,5-c 1,5 naphthyridin-4-amine methanesulfonate
EP2394650A1 (en) 2004-12-30 2011-12-14 3M Innovative Properties Co. Use of resiquimod for the treatment of cutaneous metastases
CA2594674C (en) 2004-12-30 2016-05-17 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
EP1844201B1 (en) 2005-02-04 2016-08-24 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US20080318998A1 (en) * 2005-02-09 2008-12-25 Coley Pharmaceutical Group, Inc. Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines
AU2006338521A1 (en) 2005-02-09 2007-10-11 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
EP1846405A2 (en) 2005-02-11 2007-10-24 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods
WO2006091394A2 (en) * 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
NZ560929A (en) 2005-02-18 2009-12-24 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
PT2351772T (pt) 2005-02-18 2016-09-22 Glaxosmithkline Biologicals Sa Proteínas e ácidos nucleicos de escherichia coli associada a meningite/septicemia
CA2598695A1 (en) 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
WO2006091647A2 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
CA2598639A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
AU2006216798A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
CA2602098A1 (en) 2005-03-14 2006-09-21 Graceway Pharmaceuticals, Llc Method of treating actinic keratosis
EP1863814A1 (en) 2005-04-01 2007-12-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
EP1869043A2 (en) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
AU2006241166A1 (en) * 2005-04-25 2006-11-02 3M Innovative Properties Company Immunostimulatory compositions
US20100017895A1 (en) 2005-07-18 2010-01-21 Amy Weiner Small animal model for hcv replication
BRPI0615788A2 (pt) 2005-09-09 2011-05-24 Coley Pharm Group Inc derivados de amida e carbamato de n-{2-[4-amino (etoximetil)-1h-imidazo [4,5-c] quinolin-1-il]-1,1-dimetiletil} metanossulfonamida, composição farmacêutica destes e seus usos
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
NZ567979A (en) 2005-11-04 2012-02-24 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents which is an agonist of Toll-Like Receptor 7
PL1945252T3 (pl) 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
KR20080083270A (ko) 2005-11-04 2008-09-17 콜레이 파마시티컬 그룹, 인코포레이티드 하이드록시 및 알콕시 치환된 1에이치 이미다조퀴놀린 및방법
JP2009514850A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル アジュバントとして減少した量の水中油型エマルションを有するインフルエンザワクチン
PL1951299T3 (pl) 2005-11-04 2012-07-31 Novartis Ag Szczepionki przeciw grypie zawierające kombinacje adiuwantów cząsteczkowych i czynników wzmacniających immunogenność
WO2007085969A2 (en) 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg Influenza vaccines containing hemagglutinin and matrix proteins
WO2007100634A2 (en) 2006-02-22 2007-09-07 3M Innovative Properties Company Immune response modifier conjugates
WO2007106854A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
WO2007109810A2 (en) * 2006-03-23 2007-09-27 Novartis Ag Methods for the preparation of imidazole-containing compounds
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
US8063063B2 (en) * 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
CA2646349A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
EP2019686B1 (en) 2006-03-31 2012-07-11 Novartis AG Combined mucosal and parenteral immunization against hiv
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
US8178539B2 (en) * 2006-09-06 2012-05-15 3M Innovative Properties Company Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
BRPI0716536A2 (pt) 2006-09-11 2013-09-24 Novartis Ag produÇço de vacinas de vÍrus influenza, sem a utilizaÇço de ovos
US20110045022A1 (en) 2006-12-06 2011-02-24 Theodore Tsai Vaccines including antigen from four strains of influenza virus
US20080149123A1 (en) * 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
CN101784283A (zh) 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
UA101339C2 (ru) * 2008-01-15 2013-03-25 Меда Аб Лечение заболеваний толстой кишки или предотвращение карциномы толстого кишечника с помощью имидазохинолиновых производных
WO2009111337A1 (en) 2008-03-03 2009-09-11 Irm Llc Compounds and compositions as tlr activity modulators
JP5518041B2 (ja) 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
WO2010100632A2 (en) 2009-03-06 2010-09-10 Novartis Ag Chlamydia antigens
CN105126072B (zh) 2009-03-25 2020-05-15 德克萨斯大学系统董事会 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物
NZ595689A (en) 2009-04-14 2014-03-28 Novartis Ag Compositions for immunising against staphylococcus aureus
KR20120027276A (ko) 2009-04-27 2012-03-21 노파르티스 아게 인플루엔자를 예방하기 위한 면역증강된 백신
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
AU2013203591B2 (en) * 2009-05-01 2017-01-19 University Court Of The University Of Dundee Treatment or prophylaxis of proliferative conditions
CN102639147B (zh) 2009-07-15 2015-11-25 诺华股份有限公司 Rsv f 蛋白组合物和其制作方法
DK2464658T3 (en) 2009-07-16 2014-12-15 Novartis Ag Detoxified escherichia coli immunogens
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
LT2606047T (lt) * 2010-08-17 2017-04-10 3M Innovative Properties Company Imuninio atsako modifikatoriaus junginio lipidizuotos kompozicijos, sudėtys ir būdai
WO2012080728A1 (en) 2010-12-16 2012-06-21 Astrazeneca Ab Imidazo [4, 5 -c] quinolin- 1 -yl derivative useful in therapy
AU2012211278B2 (en) 2011-01-26 2016-11-10 Glaxosmithkline Biologicals Sa RSV immunization regimen
NO2707385T3 (enExample) 2011-05-13 2018-02-17
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
CA2838158C (en) 2011-06-03 2019-07-16 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
EP3153180A1 (en) 2011-06-03 2017-04-12 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
CA2854934A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
CN112587658A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
CN105025854A (zh) 2013-01-07 2015-11-04 宾夕法尼亚大学董事会 治疗皮肤t细胞淋巴瘤的组合物和方法
EP3024476A1 (en) 2013-07-26 2016-06-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
PE20160849A1 (es) 2013-11-05 2016-09-14 3M Innovative Properties Co Formulaciones de inyeccion con base en aceite de sesamo
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
SG11201605449YA (en) 2014-01-10 2016-08-30 Birdie Biopharmaceuticals Inc Compounds and compositions for immunotherapy
WO2015144653A1 (en) 2014-03-26 2015-10-01 Glaxosmithkline Biologicals S.A. Mutant staphylococcal antigens
CN105233291A (zh) * 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
EP4001311B1 (en) 2014-07-09 2025-11-05 Birdie Biopharmaceuticals Inc. Anti-pd-l1/pd-1 combinations for treating tumors
CN105461767B (zh) * 2014-08-07 2019-03-12 富力 一种连翘苷的化学合成方法
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
WO2017046675A1 (en) * 2015-09-14 2017-03-23 Pfizer Inc. Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors
WO2017058996A1 (en) 2015-09-29 2017-04-06 The University Of Chicago Polymer conjugate vaccines
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技(北京)有限公司 用于治疗肿瘤的抗-egfr组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技(北京)有限公司 用于治疗肿瘤的抗-cd20组合
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技(北京)有限公司 用于治疗肿瘤的抗-her2组合
EP3538218A4 (en) 2016-11-09 2020-06-17 The Board of Regents of The University of Texas System METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNODODULATION
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
JP7080501B2 (ja) 2017-06-23 2022-06-06 バーディー バイオファーマシューティカルズ インコーポレイテッド 医薬品組成物
JP7197244B2 (ja) 2017-12-20 2022-12-27 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤として使用するための分岐鎖連結基を有するアミド置換イミダゾ[4,5-c]キノリン化合物
CA3091027A1 (en) 2018-02-02 2019-08-08 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
CN111788202B (zh) * 2018-02-28 2024-03-01 3M创新有限公司 具有N-1支链基团的经取代的咪唑并[4,5-c]喹啉化合物
US11059876B2 (en) 2018-02-28 2021-07-13 Pfizer Inc. IL-15 variants and uses thereof
KR102602329B1 (ko) 2018-05-23 2023-11-16 화이자 인코포레이티드 Cd3에 특이적인 항체 및 이의 용도
AU2019274655B2 (en) 2018-05-23 2023-03-09 Pfizer Inc. Antibodies specific for GUCY2c and uses thereof
CA3101277A1 (en) 2018-05-24 2019-11-28 3M Innovative Properties Company N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
CA3107305A1 (en) * 2018-07-24 2020-01-30 Torque Therapeutics, Inc. Tlr7/8 agonists and liposome compositions
EP3887369B1 (en) * 2018-11-26 2024-05-08 Solventum Intellectual Properties Company N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
WO2020163118A1 (en) * 2019-02-07 2020-08-13 Canwell Biotech Limited Phosphorus imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof
CN119455004A (zh) 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
CA3134874A1 (en) 2019-03-27 2020-10-01 Merck Patent Gmbh Imidazolonylquinoline compounds and therapeutic uses thereof
KR20220091528A (ko) 2019-10-29 2022-06-30 프라임 리치 트레이딩 리미티드 4-아미노-이미다조퀴놀린 화합물 및 이의 용도
WO2021116420A1 (en) 2019-12-13 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis
WO2021124073A1 (en) 2019-12-17 2021-06-24 Pfizer Inc. Antibodies specific for cd47, pd-l1, and uses thereof
PE20231565A1 (es) 2020-07-17 2023-10-04 Pfizer Anticuerpos terapeuticos y sus usos
AU2021327396A1 (en) 2020-08-20 2023-03-23 Ambrx, Inc. Antibody-TLR agonist conjugates, methods and uses thereof
WO2022130046A1 (en) * 2020-12-16 2022-06-23 3M Innovative Properties Company N-1 branched imidazoquinolines, conjugates thereof, and methods
WO2025104289A1 (en) 2023-11-17 2025-05-22 Medincell S.A. Antineoplastic combinations

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2135210A (en) * 1937-03-13 1938-11-01 John R Farrar Golf ball
US3314941A (en) 1964-06-23 1967-04-18 American Cyanamid Co Novel substituted pyridodiazepins
US3692907A (en) * 1970-10-27 1972-09-19 Richardson Merrell Inc Treating viral infections with bis-basic ethers and thioethers of fluorenone and fluorene and pharmaceutical compositons of the same
US3819190A (en) * 1972-10-02 1974-06-25 D Nepela Golf ball
US4284276A (en) * 1980-02-13 1981-08-18 Worst Joseph C Grooved golf ball
CA1271477A (en) * 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
JPH0327380Y2 (enExample) 1985-05-22 1991-06-13
US4880779A (en) * 1987-07-31 1989-11-14 Research Corporation Technologies, Inc. Method of prevention or treatment of AIDS by inhibition of human immunodeficiency virus
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
DE69029212T2 (de) 1989-02-27 1997-05-22 Riker Laboratories Inc 4-Amino-1H-Imidazo(4,5-c)chinoline als antivirale Mittel
US5756747A (en) 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5037986A (en) 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
US5054153A (en) * 1989-12-01 1991-10-08 Silliman Paul D Golf club cleaner
WO1992006093A1 (en) 1990-10-05 1992-04-16 Minnesota Mining And Manufacturing Company Process for the preparation of imidazo[4,5-c]quinolin-4-amines
JP2955019B2 (ja) * 1991-03-01 1999-10-04 ミネソタ マイニング アンド マニュファクチャリング カンパニー 1−置換、2−置換1H−イミダゾ〔4,5−c〕キノリン−4−アミン
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5175296A (en) 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
FR2692159B1 (fr) * 1992-06-10 1996-10-11 Vartan Berberian Boule pour jeux de boules et procedes d'obtention d'une telle boule.
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
KR100341341B1 (ko) 1993-07-15 2002-11-25 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 이미다조[4,5-c]피리딘-4-아민
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5648516A (en) 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5644063A (en) 1994-09-08 1997-07-01 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]pyridin-4-amine intermediates
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
JPH09116911A (ja) * 1995-10-20 1997-05-02 Canon Inc 撮像システム
JPH09208584A (ja) 1996-01-29 1997-08-12 Terumo Corp アミド誘導体、およびそれを含有する医薬製剤、および合成中間体
JPH09255926A (ja) 1996-03-26 1997-09-30 Diatex Co Ltd 粘着テープ
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
US5693811A (en) 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
US5759109A (en) * 1996-09-09 1998-06-02 Martini; Byron Rocco Simulated golf ball instructional device
AU724042B2 (en) 1996-10-25 2000-09-07 Minnesota Mining And Manufacturing Company Immune response modifier compounds for treatment of TH2 mediated and related diseases
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
EP0894797A4 (en) * 1997-01-09 2001-08-16 Terumo Corp NEW AMID DERIVATIVES AND INTERMEDIATES ON YOUR SYNTHESIS
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
JPH11222432A (ja) 1998-02-03 1999-08-17 Terumo Corp インターフェロンを誘起するアミド誘導体を含有する外用剤
JPH11255926A (ja) 1998-03-13 1999-09-21 Toray Ind Inc シリコーン成型品およびその製造方法
CN1220997C (zh) * 1998-05-22 2005-09-28 松下电器产业株式会社 电解电容器及其制造方法
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2000119271A (ja) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd 1h―イミダゾピリジン誘導体
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6245776B1 (en) * 1999-01-08 2001-06-12 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
EP1495758A3 (en) 1999-01-08 2005-04-13 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
JP2000247884A (ja) 1999-03-01 2000-09-12 Sumitomo Pharmaceut Co Ltd アラキドン酸誘発皮膚疾患治療剤
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
JP2002145777A (ja) 2000-11-06 2002-05-22 Sumitomo Pharmaceut Co Ltd アラキドン酸誘発皮膚疾患治療剤
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
UA74852C2 (en) * 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6664265B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6667312B2 (en) * 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
UA74593C2 (en) 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664260B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
AU3249802A (en) 2000-12-08 2002-06-18 3M Innovative Properties Co Screening method for identifying compounds that selectively induce interferon alpha
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
EP1401437A1 (en) 2001-06-15 2004-03-31 3M Innovative Properties Company Immune response modifiers for the treatment of periodontal disease
EP1427445A4 (en) 2001-08-30 2006-09-06 3M Innovative Properties Co METHODS OF MATURING PLASMOCYTOID DENDRITIC CELLS USING MOLECULES MODIFYING IMMUNE RESPONSES
WO2003094836A2 (en) 2001-10-12 2003-11-20 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
US20040014779A1 (en) 2001-11-16 2004-01-22 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like recptor pathways
AU2004220469B2 (en) 2001-11-29 2010-07-29 3M Innovative Properties Company Methods of improving skin quality
WO2003045391A1 (en) 2001-11-29 2003-06-05 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
WO2003072026A2 (en) 2002-02-22 2003-09-04 3M Innovative Properties Company Method of reducing and treating uvb-induced immunosuppression
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
US6743920B2 (en) 2002-05-29 2004-06-01 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
US6797718B2 (en) 2002-06-07 2004-09-28 3M Innovative Properties Company Ether substituted imidazopyridines
AU2003299863B2 (en) 2002-08-15 2009-09-24 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
JP2006503068A (ja) 2002-09-26 2006-01-26 スリーエム イノベイティブ プロパティズ カンパニー 1h−イミダゾダイマー
WO2004053057A2 (en) 2002-12-11 2004-06-24 3M Innovative Properties Company Gene expression systems and recombinant cell lines
AU2003287316A1 (en) 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
NZ540826A (en) * 2002-12-20 2008-07-31 3M Innovative Properties Co Aryl / hetaryl substituted imidazoquinolines
WO2004060319A2 (en) 2002-12-30 2004-07-22 3M Innovative Properties Company Immunostimulatory combinations
WO2004071459A2 (en) 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
US7485432B2 (en) 2003-02-27 2009-02-03 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
EP1601365A4 (en) 2003-03-04 2009-11-11 3M Innovative Properties Co PROPHYLACTIC TREATMENT OF UV-INDUCED EPIDERMAL NEOPLASIA
KR20050107497A (ko) 2003-03-07 2005-11-11 쓰리엠 이노베이티브 프로퍼티즈 컴파니 1-아미노 1h-이미다조퀴놀린
WO2004080293A2 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Methods for diagnosing skin lesions
AU2004220465A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
JP2006523452A (ja) 2003-03-25 2006-10-19 スリーエム イノベイティブ プロパティズ カンパニー 共通のToll様受容体を通じて媒介される細胞活性の選択的活性化
AU2004229478B2 (en) 2003-04-10 2009-12-24 3M Innovative Properties Company Delivery of immune response modifier compounds
GEP20084545B (en) 2003-09-05 2008-11-25 Anadys Pharmaceuticals Inc Introducing tlr7 ligands and prodrugs thereof for the treatment of hepatitis c viral infection

Also Published As

Publication number Publication date
IL155884A0 (en) 2003-12-23
HUP0600600A2 (en) 2006-11-28
WO2002046190A3 (en) 2003-07-17
WO2002046191A2 (en) 2002-06-13
RU2302418C2 (ru) 2007-07-10
PL366330A1 (en) 2005-01-24
TWI293300B (en) 2008-02-11
HK1069166A1 (en) 2005-05-13
HRP20030466A2 (en) 2004-06-30
WO2002046191A3 (en) 2003-03-13
US7612083B2 (en) 2009-11-03
CN1487939A (zh) 2004-04-07
US6953804B2 (en) 2005-10-11
AU3061802A (en) 2002-06-18
EE200300272A (et) 2003-10-15
WO2002046193A3 (en) 2003-02-27
EP1339715A2 (en) 2003-09-03
US20050148619A1 (en) 2005-07-07
EE200300268A (et) 2003-10-15
RU2003116649A (ru) 2005-02-10
CA2436980A1 (en) 2002-06-13
AU3953002A (en) 2002-06-18
CN1247575C (zh) 2006-03-29
BR0116470A (pt) 2005-08-16
AU2002230618B2 (en) 2006-11-02
SK6842003A3 (en) 2003-12-02
NO20032449D0 (no) 2003-05-28
CA2436846A1 (en) 2002-06-13
HRP20030463A2 (en) 2004-04-30
ZA200305275B (en) 2004-10-08
ZA200305272B (en) 2005-01-26
WO2002046188A2 (en) 2002-06-13
PL366115A1 (en) 2005-01-24
IL155904A0 (en) 2003-12-23
SK7122003A3 (en) 2003-11-04
DE60117859D1 (de) 2006-05-04
NZ526106A (en) 2004-11-26
AR035664A1 (es) 2004-06-23
NZ526088A (en) 2004-12-24
PL365907A1 (en) 2005-01-10
US6670372B2 (en) 2003-12-30
CZ20031560A3 (en) 2004-05-12
RU2308456C2 (ru) 2007-10-20
US6656938B2 (en) 2003-12-02
CN1479739A (zh) 2004-03-03
NO20032595L (no) 2003-06-06
HUP0600605A2 (en) 2006-11-28
KR20040028690A (ko) 2004-04-03
RU2351598C2 (ru) 2009-04-10
NO20032451D0 (no) 2003-05-28
DE60126645D1 (de) 2007-03-29
WO2002046192A3 (en) 2003-02-13
NO20032595D0 (no) 2003-06-06
HUP0700062A2 (en) 2007-05-02
NO20032473L (no) 2003-05-30
PL365883A1 (en) 2005-01-10
DE60117859T2 (de) 2006-11-23
DE60111076D1 (en) 2005-06-30
ATE319711T1 (de) 2006-03-15
US7049439B2 (en) 2006-05-23
PL207340B1 (pl) 2010-12-31
CA2431151A1 (en) 2002-06-13
JP4437189B2 (ja) 2010-03-24
EE200300275A (et) 2003-10-15
MXPA03005011A (es) 2003-09-05
CZ295848B6 (cs) 2005-11-16
AU3248202A (en) 2002-06-18
AU2002239517B2 (en) 2006-11-02
NZ526086A (en) 2005-11-25
HRP20030467B1 (hr) 2009-04-30
UA75622C2 (en) 2006-05-15
MXPA03005012A (es) 2003-09-05
JP2004532810A (ja) 2004-10-28
WO2002046193A2 (en) 2002-06-13
SI1341790T1 (sl) 2007-06-30
KR20040047733A (ko) 2004-06-05
US20030158192A1 (en) 2003-08-21
AR035667A1 (es) 2004-06-23
CA2436983A1 (en) 2002-06-13
CZ20031562A3 (en) 2004-03-17
EP1343784A2 (en) 2003-09-17
HRP20030462A2 (en) 2004-04-30
JP2004529078A (ja) 2004-09-24
CZ20031563A3 (cs) 2004-02-18
US20040092545A1 (en) 2004-05-13
HRP20030461A2 (en) 2004-06-30
CA2436846C (en) 2010-11-16
PL365995A1 (en) 2005-01-24
SK7102003A3 (en) 2003-10-07
AU3249702A (en) 2002-06-18
AR035669A1 (es) 2004-06-23
HUP0400704A2 (hu) 2004-06-28
BR0116464A (pt) 2006-02-21
ES2281456T3 (es) 2007-10-01
BR0116052A (pt) 2006-02-21
CA2436980C (en) 2011-03-29
CN1479738A (zh) 2004-03-03
AU2002239530B2 (en) 2006-09-28
NO20032596L (no) 2003-06-06
NO326159B1 (no) 2008-10-13
US20030212091A1 (en) 2003-11-13
KR20030070050A (ko) 2003-08-27
TWI222972B (en) 2004-11-01
HK1064383A1 (en) 2005-01-28
AR035666A1 (es) 2004-06-23
US20050234088A1 (en) 2005-10-20
JP2004515500A (ja) 2004-05-27
IL156043A0 (en) 2003-12-23
AU3951702A (en) 2002-06-18
CN1253452C (zh) 2006-04-26
BR0116047A (pt) 2003-09-30
BR0116032A (pt) 2006-02-21
AR035665A1 (es) 2004-06-23
EE200300274A (et) 2003-10-15
KR20030070049A (ko) 2003-08-27
US7132429B2 (en) 2006-11-07
NZ526105A (en) 2004-11-26
EP1341791A2 (en) 2003-09-10
ES2242782T3 (es) 2005-11-16
WO2002046188A3 (en) 2003-03-13
JP2010031040A (ja) 2010-02-12
ATE353895T1 (de) 2007-03-15
CN1511155A (zh) 2004-07-07
EP1343784B1 (en) 2006-03-08
DK1341791T3 (da) 2005-09-19
RU2003116059A (ru) 2005-02-10
AU2002232482B2 (en) 2006-10-19
CN1894244A (zh) 2007-01-10
WO2002046192A2 (en) 2002-06-13
DK1343784T3 (da) 2006-07-10
CZ20031591A3 (cs) 2003-11-12
IL156044A0 (en) 2003-12-23
EP1341791B1 (en) 2005-05-25
EP1341792A2 (en) 2003-09-10
RU2003116123A (ru) 2004-11-20
NO20032473D0 (no) 2003-05-30
MXPA03004975A (es) 2003-09-05
PT1341791E (pt) 2005-09-30
KR20040023576A (ko) 2004-03-18
CN1537111A (zh) 2004-10-13
CN1297554C (zh) 2007-01-31
EE200300271A (et) 2003-10-15
BR0116026A (pt) 2004-12-21
SK7132003A3 (en) 2003-10-07
CY1106569T1 (el) 2012-01-25
SK7112003A3 (en) 2003-12-02
DK1341790T3 (da) 2007-06-04
EP1341790A2 (en) 2003-09-10
ES2260323T3 (es) 2006-11-01
ZA200305273B (en) 2004-10-08
SK7152003A3 (en) 2003-09-11
TW584633B (en) 2004-04-21
DE60111076T2 (de) 2006-05-04
IL155903A0 (en) 2003-12-23
PT1341790E (pt) 2007-05-31
ZA200305271B (en) 2004-10-08
JP2004523498A (ja) 2004-08-05
AU2002239516B2 (en) 2006-11-09
NO20032449L (no) 2003-05-28
ATE296301T1 (de) 2005-06-15
US20040106640A1 (en) 2004-06-03
CY1105586T1 (el) 2010-07-28
NO20032596D0 (no) 2003-06-06
NZ526087A (en) 2004-11-26
HUP0600338A2 (en) 2006-08-28
EP1341790B1 (en) 2007-02-14
NZ526089A (en) 2004-11-26
DE60126645T2 (de) 2007-11-22
HUP0400710A2 (hu) 2004-06-28
SK287264B6 (sk) 2010-04-07
RU2315049C2 (ru) 2008-01-20
EP1341789A2 (en) 2003-09-10
MXPA03004974A (es) 2003-09-05
SK287732B6 (en) 2011-07-06
AU2002232497B2 (en) 2006-11-02
JP2004521092A (ja) 2004-07-15
AU3951602A (en) 2002-06-18
WO2002046190A2 (en) 2002-06-13
WO2002046189A2 (en) 2002-06-13
CZ20031592A3 (cs) 2004-01-14
KR20040028691A (ko) 2004-04-03
NO20032452L (no) 2003-07-16
RU2003116063A (ru) 2004-12-10
EE200300270A (et) 2003-10-15
MXPA03004973A (es) 2004-01-29
US20040077678A1 (en) 2004-04-22
ZA200305270B (en) 2004-08-26
NO20032452D0 (no) 2003-05-28
IL155950A0 (en) 2003-12-23
MXPA03004972A (es) 2004-01-29
US6683088B2 (en) 2004-01-27
PL392462A1 (pl) 2010-11-22
NO20032451L (no) 2003-07-16
ZA200305274B (en) 2004-10-18
CA2436984A1 (en) 2002-06-13
CZ20031561A3 (cs) 2004-04-14
US20020193396A1 (en) 2002-12-19
CZ303462B6 (cs) 2012-09-26
JP2004515501A (ja) 2004-05-27
HRP20030467A2 (en) 2004-04-30
WO2002046189A3 (en) 2003-03-20
CN1252070C (zh) 2006-04-19
HRP20030464A2 (en) 2004-06-30
UA74852C2 (en) 2006-02-15
PL361948A1 (en) 2004-10-18
CA2430844A1 (en) 2002-06-13
HK1066005A1 (en) 2005-03-11

Similar Documents

Publication Publication Date Title
AR035668A1 (es) Imidazoquinolinas y 6,7,8,9-tetrahidroimidazoquinolinas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos
JP5615902B2 (ja) イミダゾ[2,1−b][1,3,4]チアジアゾール誘導体
AR048340A1 (es) Compuestos de acido alfa aril o heteroaril metil beta piperidino propanoico como antagonistas del receptor orl1, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para tratar enfermedades mediadas por orl1.
AR045261A1 (es) Compuestos que contienen imidazo quinolina o imidazo piridina sustituidos; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos inmunomoduladores
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
PE20020721A1 (es) Derivados de quinuclidina como agentes antimuscarinicos m3
BRPI0112475B8 (pt) n-óxido de derivados 4-fenil-piridina como antagonista de receptor nk1, seu medicamento, seu processo de preparação e seus usos
UY30411A1 (es) Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
AR078045A1 (es) Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer
UY27781A1 (es) Compuestos químicos.
AR035670A1 (es) Imidazopiridinas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos
HUP0302167A2 (hu) Metabotropikus glutamát receptor antagonista hatású kinolinszármazékok, a vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
AR040278A1 (es) Ligandos del receptor de glucocorticoides para el tratamiento de trastornos metabolicos
AR052902A1 (es) Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa
HRP20041137B1 (hr) Indolni, azaindolni i srodni heterocikliäśni 4-alkenil piperidinski amidi
AR038864A1 (es) Inhibidores pirimidina y piridina biciclicos de la p38 quinasa
ATE440834T1 (de) Substituierte arylaminderivate und verwendungsverfahren
BRPI0607600A2 (pt) derivados de 4-oxoquinazolin-3-il-benzamida para o tratamento de doenças relacionadas com citocina
PE20050141A1 (es) DERIVADOS DE 2-ALQUINIL-Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIDINA COMO ANTAGONISTAS DEL RECEPTOR A2a ADENOSINA
AR085750A1 (es) Derivados de pirazolo-pirimidina
ECSP088257A (es) Derivados de amida
AR042002A1 (es) Benzoxazinonas sustituidas, proceso de obtencion y usos para tratamiento de enfermedades del sistema nervioso central.
AR065297A1 (es) Formulaciones biodisponibles de compuestos heterociclicos
WO2008077810A3 (en) Spiro-piperidine derivatives
AR042284A1 (es) Derivados de piperidina, preparacion y composiciones farmaceuticas que las contienen; y uso de los mismos para la fabricacion de medicamentos

Legal Events

Date Code Title Description
FB Suspension of granting procedure